A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

被引：0
|
作者：
Alison M. Schram
Leena Gandhi
Monica M. Mita
Lars Damstrup
Frank Campana
Manuel Hidalgo
Enrique Grande
David M. Hyman
Rebecca S. Heist
机构：
[1] Memorial Sloan Kettering Cancer Center,
[2] New York University Perlmutter Cancer Center,undefined
[3] Cedars-Sinai Medical Center,undefined
[4] Merck Serono,undefined
[5] Sanofi-Aventis,undefined
[6] Beth Israel Deaconess Medical Center,undefined
[7] Hospital Universitario Ramon y Cajal,undefined
[8] Massachusetts General Hospital,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1471 / 1476
页数：5
相关论文
共 50 条
  • [21] Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Eskens, Ferry
    Blumenschein, George, Jr.
    Richards, Donald
    Genvresse, Isabelle
    Reschke, Susanne
    Granvil, Camille
    Skubala, Adam
    Pena, Carol
    Mross, Klaus
    TARGETED ONCOLOGY, 2020, 15 (02) : 163 - 174
  • [22] Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Ferry Eskens
    George Blumenschein
    Donald Richards
    Isabelle Genvresse
    Susanne Reschke
    Camille Granvil
    Adam Skubala
    Carol Peña
    Klaus Mross
    Targeted Oncology, 2020, 15 : 163 - 174
  • [23] Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors
    Infante, Jeffrey R.
    Gandhi, Leena
    Shapiro, Geoffrey
    Burris, Howard A.
    Bendell, Johanna C.
    Baselga, Jose
    Hsu, Karl
    Faivre, Thea
    Asatiani, Ekatherine
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
    Falchook, Gerald S.
    Lewis, Karl D.
    Infante, Jeffrey R.
    Gordon, Michael S.
    Vogelzang, Nicholas J.
    DeMarini, Douglas J.
    Sun, Peng
    Moy, Christopher
    Szabo, Stephen A.
    Roadcap, Lori T.
    Peddareddigari, Vijay G. R.
    Lebowitz, Peter F.
    Le, Ngocdiep T.
    Burris, Howard A., III
    Messersmith, Wells A.
    O'Dwyer, Peter J.
    Kim, Kevin B.
    Flaherty, Keith
    Bendell, Johanna C.
    Gonzalez, Rene
    Kurzrock, Razelle
    Fecher, Leslie A.
    LANCET ONCOLOGY, 2012, 13 (08): : 782 - 789
  • [25] Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
    Park, Haeseong
    Garrido-Laguna, Ignacio
    Naing, Aung
    Fu, Siqing
    Falchook, Gerald S.
    Piha-Paul, Sarina A.
    Wheler, Jennifer J.
    Hong, David S.
    Tsimberidou, Apostolia M.
    Subbiah, Vivek
    Zinner, Ralph G.
    Kaseb, Ahmed O.
    Patel, Shreyaskumar
    Fanale, Michelle A.
    Velez-Bravo, Vivianne M.
    Meric-Bernstam, Funda
    Kurzrock, Razelle
    Janku, Filip
    ONCOTARGET, 2016, 7 (41) : 67521 - 67531
  • [26] Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Ferry Eskens
    George Blumenschein
    Donald Richards
    Isabelle Genvresse
    Susanne Reschke
    Camille Granvil
    Adam Skubala
    Carol Peña
    Klaus Mross
    Targeted Oncology, 2020, 15 : 803 - 803
  • [27] Phase I Dose-escalation Study of the Oral Selective C-Met Inhibitor EMD 1204831 in Patients With Advanced Solid Tumours
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Tsimberdiou, A. M.
    Hong, D. S.
    Naing, A.
    Klevesath, M. B.
    Mattiacci, M. R.
    Johne, A.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S158 - S158
  • [28] A Phase I Dose-escalation Study of EMD 1214063, an Oral Selective C-Met Inhibitor, in Patients With Advanced Solid Tumours
    Falchook, G. S.
    Fu, S.
    Amin, H. M.
    Piha-Paul, S. A.
    Hong, D. S.
    Naing, A.
    Klevesath, M. B.
    Mattiacci, M. R.
    Di Cara, A.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S158 - S158
  • [29] Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
    Wen, Patrick Y.
    Omuro, Antonio
    Ahluwalia, Manmeet S.
    Fathallah-Shaykh, Hassan M.
    Mohile, Nimish
    Lager, Joanne J.
    Laird, A. Douglas
    Tang, Jiali
    Jiang, Jason
    Egile, Coumaran
    Cloughesy, Timothy F.
    NEURO-ONCOLOGY, 2015, 17 (09) : 1275 - 1283
  • [30] A phase I dose-escalation study of buparlisib (BKM120), an oral pan-PI3K inhibitor, in Chinese patients with advanced solid tumors
    Zhang, L.
    Xu, B.
    Hazell, K.
    Gaur, A.
    Xu, J.
    Trandafir, L.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S186
12345